A sickle cell cure exists. But patients need more than just gene therapy.
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...
Agios Pharmaceuticals Q3 2024 Earnings Preview
Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. The consensus EPS Estimate is $7.91 and the consensus Revenue Estimate ...
Crain's New York6d
Pfizer CEO, under fire, will do ‘whatever it takes’ to grow
Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...
Pfizer Inc (PFE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...
Pfizer CEO Defends Turnaround Strategy as Activist Pressures Management
(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a ...
Pfizer, Inc. (PFE) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...
Pfizer Earnings: Maintaining Our Valuation as Management Pressed for Evidence of Productivity
We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.
Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...